Peptides
Tesamorelin
Also called Egrifta
Tesamorelin is best known for reducing deep abdominal fat around the organs. It has a specific approved use in adults with HIV-associated lipodystrophy; that does not make it a general weight-loss drug or a reliable way to remove pinchable belly fat.
Dosage & duration
Current US Egrifta WR label for eligible adults with HIV-associated lipodystrophy.
Egrifta WR formulation
Product label- Dose
- 1.28 mg
- How often
- Once daily, under the skin
- How long
- Ongoing treatment with response reassessment
WR-specific; not interchangeable with other Egrifta formulations or products sold as research tesamorelin.
Sources: 1
The pivotal clinical studies assessed outcomes at about six months; they do not define a bodybuilding cycle.
The practical difference
Two kinds of belly fat, different expectations
| What differs | Visceral fat | Subcutaneous fat |
|---|---|---|
| Where it sits | Deeper, around the organs | Under the skin—the pinchable layer |
| Evidence on this page | The principal treatment target | A different endpoint; the cited obesity trial found no significant reduction |
Which belly fat does it address?
Visceral fat sits deeper around organs. Subcutaneous fat is the layer under the skin that you can pinch. Tesamorelin’s main clinical evidence concerns the first; a smaller waist or a flatter appearance is not guaranteed for every body-fat pattern.
How it differs from appetite medicines
Tesamorelin stimulates growth-hormone release. It is not a GLP-1 appetite treatment, and the Egrifta label explicitly says it is not for weight-loss management. A selected obesity trial also found a visceral-fat effect, but does not establish broad cosmetic use.
Why this is not a quick cutting cycle
Pivotal results were assessed over months, and excess visceral fat returned after treatment stopped. Formulation matters: the current WR amount is not a milligram-for-milligram replacement for earlier Egrifta or an unverified vial.
What follow-up needs to cover
Raised IGF-1, glucose changes, fluid retention and joint symptoms belong in the treatment discussion. Active cancer, pregnancy and certain pituitary disorders are among the label’s exclusions.
Dose references and context Existing reported protocols; not personal dosing instructions
This older catalog material includes research and community reports. It has not all been source-checked in this page update and should not be treated as a dosing recommendation.
EGRIFTA WR labeled HIV-associated lipodystrophy use
1.28 mg · Subcutaneous · Once daily
WR-specific prescribing-information context. Not interchangeable with other EGRIFTA formulations; clinical monitoring and contraindications apply.
Model details: Tesamorelin · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Single EGRIFTA WR1.28mg SC dose in healthy subjects, same label study. Original2mg Egrifta26/38min values came after14days, not this single-dose WR formulation.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.1833333 hours
- Absorption half-life assumed
- 0.06452204 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 0.15 h source-scoped peak time; absorption half-life 0.06452204183467626 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Peak/Tmax/tail reconstruction gives AUC1.7866ng·h/mL versus1.172reported (+52.4%); do not call all endpoints reproduced.
- Either explicitly identify WR in model scope or keep generic formulation relative; never relabel saved2mg inputs as1.28mg.
- No additional F multiplier because peak includes availability.
- Source variability is large; means of endpoints need not define one typical individual curve.
- EGRIFTA WR US label March2025,12.3
Healthy single1.28mgSC: Cmax3831pg/mL,Tmax.15h,t1/2 11min,AUCinf1172pg·h/mL. WR and SV are not substitutable; exposure at WR1.28mg resembles original Egrifta2mg.
- Original EGRIFTA label2010,12.3
Original2mgSC single dose peak2874.6pg/mL in healthy subjects;26min tail reported after14consecutive doses. OriginalSC F<4%, not50%.
tesamorelin-relative-timing-2026-10 · version 1
Common questions
Is tesamorelin a weight-loss drug?
The Egrifta WR label says it is not for weight-loss management. Its approved purpose is excess abdominal fat in HIV-associated lipodystrophy.
Will the fat stay off after stopping?
The clinical programme observed return of excess visceral fat after stopping; permanence should not be promised.
Sources Labels, studies and notes behind this guide
Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main target
- Not guaranteed removal of the layer you can pinch.
- Approved setting
- Not general weight management.
- After stopping
- A short course is not a permanent result.
- 1. Egrifta WR US label
WR 1.28 mg daily is formulation-specific. HIV lipodystrophy indication, not general weight management; glucose and IGF-1 monitoring.
- 2. Tesamorelin obesity randomized trial
Selected adults with obesity and reduced GH secretion; visceral-fat effect without significant subcutaneous-fat effect.
- 3. Egrifta patient information
Manufacturer describes return of excess visceral fat after stopping treatment in studies.
- 4. EGRIFTA WR US label March2025,12.3
Healthy single1.28mgSC: Cmax3831pg/mL,Tmax.15h,t1/2 11min,AUCinf1172pg·h/mL. WR and SV are not substitutable; exposure at WR1.28mg resembles original Egrifta2mg.
- 5. Original EGRIFTA label2010,12.3
Original2mgSC single dose peak2874.6pg/mL in healthy subjects;26min tail reported after14consecutive doses. OriginalSC F<4%, not50%.
- 6. EGRIFTA WR FDA prescribing information, 2025
Current WR formulation: 1.28 mg SC daily; reduction of excess abdominal fat in adults with HIV lipodystrophy, not weight-loss management.
- 7. EGRIFTA original prescribing information
Original 2 mg formulation; used to explain why old dosing information cannot be transferred between formulations.
Keep reading
Related compounds and examples
Related compounds
CJC-1295 with DAC
CJC-1295 with DAC appeals to people seeking longer-lasting GH stimulation with fewer injections. Compare reported weekly use, trial doses, recovery goals and the trade-offs.
CJC-1295 without DAC (Modified GRF 1-29)
CJC-1295 no DAC is sought for better sleep, workout recovery and a leaner physique, often with ipamorelin. Compare reported doses, duration and the daily-use trade-off.
Sermorelin
Sermorelin for sleep and recovery: reported clinic doses, treatment time and differences from HGH.